New cocktail therapy targets liver cancer that resists immunotherapy
NCT ID NCT07157306
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—gecacitinib, donafenib, and a PD-1 inhibitor—as a second-line treatment for people with advanced liver cancer that did not respond to initial immunotherapy. The study will enroll 35 participants and measure how well the treatment shrinks tumors and controls the disease, while also tracking side effects. The goal is to see if this drug cocktail can offer a new option when standard immunotherapy stops working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gecacitinib, donafenib, and a PD-1 inhibitor (a type of immunotherapy)
- What this could lead to
- If successful, this could offer a new second-line treatment option for people with advanced liver cancer whose disease worsened after initial immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 35 participants, so results may not apply widely. The combination of three drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?